Search Results

BlueWind Medical, Ltd., a pioneer in the development and commercialization of a patient centric implantable Tibial NeuroModulation (iTNM) solution for urge urinary incontinence (UUI), is excited to announce that Revi is now available in Springfield, Ohio at Ohio Valley Surgical Hospital with urologist Dr. Eric Espinosa.

BlueWind Medical, Ltd. today announced that the US Food and Drug Administration (FDA) granted a De Novo marketing request for the Revi System, a transformative tibial neuromodulation therapy for the treatment of the symptoms of urgency incontinence alone or in combination with urinary urgency.

BlueWind Medical, Ltd., the developer of a transformative implantable tibial neuromodulation therapy for Overactive Bladder (OAB), today announced results from the OASIS pivotal trial evaluating the safety and efficacy of the BlueWind System in the treatment of OAB.

BlueWind Medical, Ltd., a medical device company transforming neuromodulation therapy for overactive bladder, announced three executive appointments to leadership positions within the company.

BlueWind Medical, Ltd. is pleased to announce that the American Medical Association has issued a new Current Procedural Terminology code for the subfascial implantation of a tibial neuromodulation device for Overactive Bladder.

BlueWind Medical, Ltd., the developer of transformative implantable tibial neuromodulation therapy for Overactive Bladder (OAB), today announced that efficacy results of the OASIS pivotal clinical study will be presented in a late breaking session at the American Urological Association (AUA) 2023 Annual Meeting, being held in Chicago April 27th- May 1st.

BlueWind Medical, Ltd. announced that Liz Kwo, M.D., MBA, MPH, Chief Medical Officer at Everly Health, has joined the company’s Board of Directors.

BlueWind Medical, Ltd., a pioneer in the development and commercialization of a patient-centric implantable Tibial NeuroModulation (iTNM) solution for urge urinary incontinence (UUI), is excited to announce that Revi is now available in Utah with urologist Dr. Sara Lenherr at the University of Utah.

BlueWind Medical, Ltd. today announced that Dr. Osvaldo Padron of Florida Urology Partners in Tampa, Florida, has treated the first patient in the RESTORE study, a prospective, multi-center, open label, post market, randomized controlled trial.